Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OV329 add-on therapy in adults with drug-resistant focal epilepsy
CTR20263805Phase 2Active
- Sponsor
- Shanghai Dimaihe Biotechnology
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of OV329 in Focal Onset Epilepsy, sponsored by Shanghai Dimaihe Biotechnology. Started Oct 2026; status: active.
02
Drugs
OV329
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on CTR20263805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263805.